| [1] |
VIRANI S A, DENT S, BREZDEN-MASLEY C, et al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy[J]. Can J Cardiol, 2016, 32(7): 831-841.
|
| [2] |
KONG F H, YE Q F, MIAO X Y, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma[J]. Theranostics, 2021, 11(11): 5464-5490.
|
| [3] |
BRIELER J, BREEDEN M A, TUCKER J. Cardiomyopathy: An overview[J]. Am Fam Physician, 2017, 96(10): 640-646.
|
| [4] |
CHAAR M, KAMTA J, AIT-OUDHIA S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities[J]. Onco Targets Ther, 2018, 11: 6227-6237.
|
| [5] |
SCHLITT A, JORDAN K, VORDERMARK D, et al. Cardiotoxicity and oncological treatments[J]. Dtsch Arztebl Int, 2014, 111(10): 161-168.
|
| [6] |
ABDEL-RAHMAN O, FOUAD M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis[J]. Future Oncol, 2014, 10(12): 1981-1992.
|
| [7] |
DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
|
| [8] |
GUO L L, HU C T, YAO M W, et al. Mechanism of sorafenib resistance associated with ferroptosis in HCC[J]. Front Pharmacol, 2023, 14: 1207496.
|
| [9] |
刘洋, 贾孟晓, 赵婷, 等. 基于UPLC-Q-Exactive Orbitrap-MS和网络药理学的芪参益气滴丸治疗心肌缺血的配伍机制研究[J]. 中国中药杂志, 2024, 49(14): 3769-3783.
|
| [10] |
CHEN J R, WEI J, WANG L Y, et al. Cardioprotection against ischemia/reperfusion injury by QiShenYiQi Pill® via ameliorate of multiple mitochondrial dysfunctions[J]. Drug Des Devel Ther, 2015, 9: 3051-3066.
|
| [11] |
WU L L, FAN Z Y, GU L F, et al. QiShenYiQi dripping pill alleviates myocardial ischemia-induced ferroptosis via improving mitochondrial dynamical homeostasis and biogenesis[J]. J Ethnopharmacol, 2023, 308: 116282.
|
| [12] |
詹玲君, 秦伟彬, 何贵新, 等. 基于mitoKATP/PI3K/mTOR探讨芪参益气滴丸影响H9C2心肌细胞损伤后钙稳态及炎性环境的机制[J]. 时珍国医国药, 2023, 34(9): 2087-2090.
|
| [13] |
BALACHANDRAN L, HAW T J, LEONG A J W, et al. Cancer therapies and cardiomyocyte viability: Which drugs are directly cardiotoxic?[J]. Heart Lung Circ, 2024, 33(5): 747-752.
|
| [14] |
TANG W W, CHEN Z Y, ZHANG W L, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1): 87.
|
| [15] |
LI Z X, YU Y J, BU Y, et al. QiShenYiQi pills preserve endothelial barrier integrity to mitigate sepsis-induced acute lung injury by inhibiting ferroptosis[J]. J Ethnopharmacol, 2024, 322: 117610.
|
| [16] |
HUANG Y T, ZHANG K, LIU M, et al. An herbal preparation ameliorates heart failure with preserved ejection fraction by alleviating microvascular endothelial inflammation and activating NO-cGMP-PKG pathway[J]. Phytomedicine, 2021, 91: 153633.
|
| [17] |
胡 越, 阮益莉, 龚子莹, 等. 基于网络药理学和实验验证探讨芪参益气滴丸预防心肌缺血再灌注损伤的机制[J]. 中药药理与临床, 2025, 41(4): 61-67.
|
| [18] |
ZHANG S Y, WANG H, LI L X, et al. Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose-induced injury in cardiomyocytes[J]. J Cell Mol Med, 2019, 23(9): 6393-6402.
|
| [19] |
刘耀武. 四逆汤联合溶栓治疗急性心肌梗死缺血再灌注损伤及对患者动态心电图和SOD、CK-MB、LDH的影响[J]. 陕西中医, 2019, 40(7): 858-860.
|
| [20] |
刘满义. 心脏彩超联合血清心肌损伤标志物诊断急性心肌梗死的价值分析[J]. 临床研究, 2020, 28(10): 146-148.
|
| [21] |
JIANG X J, STOCKWELL B R, CONRAD M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282.
|
| [22] |
WU X G, LI Y, ZHANG S C, et al. Ferroptosis as a novel therapeutic target for cardiovascular disease[J]. Theranostics, 2021, 11(7): 3052-3059.
|
| [23] |
WANG B Q, WANG Y, ZHANG J, et al. ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis[J]. Arch Toxicol, 2023, 97(6): 1439-1451.
|
| [24] |
MA W Z, LIU M, LIANG F F, et al. Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis[J]. Basic Clin Pharmacol Toxicol, 2020, 126(2): 166-180.
|
| [25] |
WANG C, ZENG J, LI L J, et al. Cdc25A inhibits autophagy-mediated ferroptosis by upregulating ErbB2 through PKM2 dephosphorylation in cervical cancer cells[J]. Cell Death Dis, 2021, 12(11): 1055.
|
| [26] |
JIANG H, WANG C, ZHANG A, et al. ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis[J]. Biomed Pharmacother, 2022, 153: 113280.
|
| [27] |
王新羽, 张霖柯, 符艾青, 等. 铁死亡在心血管疾病中的研究进展[J]. 中国现代医学杂志, 2022, 32(17): 61-66.
|
| [28] |
TANG D L, CHEN X, KANG R, et al. Ferroptosis: molecular mechanisms and health implications[J]. Cell Res, 2021, 31(2): 107-125.
|
| [29] |
STOCKWELL B R, FRIEDMANN ANGELI J P, BAYIR H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease[J]. Cell, 2017, 171(2): 273-285.
|